Vertex Pharmaceuticals Inc
Most Recent
How Did Tesla Become Renaissance Technologies’ Gem?
In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.
Renaissance Technologies: Top Investments
Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.
Amarin’s Q2 Earnings and Robust 2019 Outlook
Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.
Vertex Pharmaceuticals Raises Guidance, Shares Follow
Yesterday, Vertex Pharmaceuticals reported its second-quarter results after the market closed. Today, it was up 1.73% in the premarket session.
Analysts Have Raised Their Target Price for VRTX in March
Wall Street analysts expect a potential upside of 14.17% for Vertex Pharmaceuticals (VRTX) based on the stock’s closing price on March 21.
Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday
On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.
A Look at Sarepta Therapeutics’ Recent Developments
In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.
How Is Sarepta Therapeutics Positioned in January?
In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.
Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.
Vertex Pharmaceuticals’ Gross Margin Trends
Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.
Do Analysts See Any Upside for Vertex Stock?
Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”
Taking Stock of Vertex’s Performance
Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.
Do Analysts See Any Upside for bluebird bio Stock?
In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.
Understanding bluebird bio’s Operational Performance
In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
How Is Vertex Pharmaceuticals Positioned in October?
Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.
Analysts Are Mostly Positive on Neurocrine Biosciences
On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.
Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
How Vertex Pharmaceuticals Is Positioned Financially
In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million.
Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space
Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter.
Estimates and Recommendations for Bluebird Bio on September 6
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.
Bluebird Bio’s Valuation on September 6
Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.
How BioMarin Pharmaceutical Is Positioned Financially in August
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.
How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.
An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept
Roche’s CellCept generated revenues of 333.0 million Swiss francs in H1 2018 compared to 346.0 million Swiss francs in H1 2017.
A Look at Incyte’s Valuation on August 22
On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.
Why Vertex Is Expected to Report Robust EPS Growth in 2018
Wall Street analysts have projected Vertex Pharmaceuticals’ fiscal 2018 adjusted diluted EPS to be around $3.8, which would be a YoY rise of approximately 93.1%.
Analyst Recommendations for Exelixis in August
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.
Analysts Are Bullish on Sarepta Therapeutics
Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.
How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?
BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.
Why Most Analysts Are Bullish on Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) is expected to incur selling, general, and administrative expenses of $117.10 million in Q2 2018 as compared with $92.91 million in Q2 2017.
Will Vertex Pharmaceuticals Meet Analysts’ Q2 Expectations?
Analysts expect Vertex Pharmaceuticals’ revenues to increase by 31.65% from $516.91 million in Q2 2017 to $680.53 million in Q2 2018.
How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release
Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.
What’s behind Gemphire Therapeutics’ Stock Price Rise
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.
Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.
How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.
Could Symdeko Be Vertex Pharmaceuticals’ Long-Term Growth Driver?
In June, Health Canada approved Vertex Pharmaceuticals’ Symdeko for the treatment of the underlying cause of cystic fibrosis in individuals over 12 years old.
Solid Biosciences’ Stock Price Rose 46.6% on June 19
On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.
CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent
On June 19, the co-owners of intellectual property associated with CRISPR-Cas9 genome editing technology were granted a US patent.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.
CRISPR Stock Has Seen Soild Growth in the Last 12 Months
CRISPR Therapeutics has risen 24% between May 11 and May 17.
How Did Jazz Pharmaceuticals Perform in 1Q18?
In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17.
How Did Exelixis Perform in 1Q18?
In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.
How Vertex Pharmaceuticals’ Drugs Performed in 1Q18
In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.
Analysts’ Recommendations for BioMarin Pharmaceutical
In March 2018, the EMA (European Medicines Agency) accepted BioMarin Pharmaceutical’s (BMRN) marketing authorization application for pegvaliase.
Why Regeneron Pharmaceuticals’ Stock Price Fell
Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”
Alexion Pharmaceuticals in 4Q17 and Fiscal 2017
In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.
Inside Pfizer’s Rare Disease Segment Performance in 2017
In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.
How Did Kalydeco Perform in 4Q17 and 2017?
In 4Q17, Vertex Pharmaceuticals’ (VRTX) Kalydeco generated revenues of $256 million, a ~45% increase on a year-over-year (or YoY) basis and 20% growth on a quarter-over-quarter (or QoQ) basis.
Gilead Sciences on the Street in January: Analyst Recommendations
In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.
Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients
Vertex Pharmaceuticals (VRTX) is currently involved in evaluating four triple combination regimens comprised of tezacaftor, ivacaftor, and one of the next-generation correctors.
Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline
On January 10, 2018, Vertex Pharmaceuticals announced that Orkambi has secured regulatory approval from the European Commission to treat CF patients ages six to 11 years.
Analyst Recommendations for Vertex Pharmaceuticals in January
Of the 27 analysts covering Vertex Pharmaceuticals in January 2018, ten have recommended a “strong buy,” while 13 have recommended a “buy.”
Analysts’ Recommendations for Bioverativ in January 2018
Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.
A Look at Ionis’s 3Q17 Revenue Stream
Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.
How’s Incyte’s Valuation in January 2018?
Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.
Analysts’ Recommendations for Eli Lilly in December 2017
Eli Lilly (LLY) stock has risen 16.1% over the last 12 months and 15.7% in 2017 year-to-date. Analysts are estimating the stock could fall 8.3% over the next 12 months.
Analyst Recommendations for Alexion in December 2017
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Analysts’ Recommendations for Regeneron
Dupilumab could be long-term growth driver In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety and efficacy of dupilumab for the treatment of individuals with severe steroid-dependent asthma. In the study, at 24 weeks, when […]
Analyst Recommendations for Vertex Pharmaceuticals in October
After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.
Gauging Alexion’s 2018 Growth with Soliris
In 2Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of ~$814 million, which represented a ~16% YoY rise and a ~4% QoQ rise.
Analysts’ Recommendations for Mylan in September 2017
In 2Q17, Mylan reported revenues close to $3.0 billion, which is a YoY rise of around 16.0%, mainly driven by increased sales in Europe and the Rest of World markets.
Analysts’ Recommendations for Regeneron in September 2017
Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”
How Is Jazz’s Defitelio Positioned after 2Q17?
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
How Are Orkambi and Kalydeco Positioned after 2Q17?
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.
Vertex Presented Successful Results for Cystic Fibrosis Treatment
Vertex Pharmaceuticals’ peers that are actively conducting research and development for CF drugs include Pfizer (PFE), PTC Therapeutics (PTCT), Proteostasis Therapeutics (PTI), Novartis, and Roche.
Vertex Saw Successful Results from VX-440 Phase 2 Study
The positive data from the clinical trials will likely help Vertex Pharmaceuticals commercialize the drug.
How Pfizer’s Rare Disease Franchise Stands after 2Q17
In 1H17, BeneFix generated revenues of ~$302 million, which reflected an ~18% decline on a YoY basis.
Analyst Recommendations for Regeneron Pharmaceuticals in August
Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”
New Patients and Alexion Pharmaceuticals’ Metabolic Franchise
Alexion Pharmaceuticals (ALXN) has reiterated its 2017 revenue guidance of $375.0 million–$400.0 million for its metabolic franchise.
Alexion Pharmaceuticals Expects Robust Revenue for Soliris
Alexion Pharmaceuticals (ALXN) raised its 2017 revenue projections for Soliris from $3.025 billion–$3.1 billion to $3.075 billion–$3.125 billion.
Alexion Pharmaceuticals Raised 2017 Earnings Guidance
Alexion Pharmaceuticals (ALXN) raised its 2017 non-GAAP guidance from the previously estimated $5.10–$5.30 to $5.40–$5.55.
Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
Bioverativ Expected to Report Healthy Profit Margins in 2017
Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.
Bioverativ Expected to Report Robust Revenue Growth in 2017
In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.
Bioverativ–True North Therapeutics: Stronger Research Pipeline
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).
Vertex Pharmaceuticals’ Focus on Innovative Combination Regimens
On March 28, 2017, Vertex Pharmaceutical (VRTX) released data from a phase 3 trial, EVOLVE.
Vertex Pharmaceuticals: Robust Growth Trends for Kalydeco in 2017
In 1Q17, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues close to $186 million, of which $102 million came from the US market.
Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
What Drove Biogen Stock in 2Q17?
Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.
What to Expect from BioMarin Pharmaceuticals in 2017
In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).
Inside Vertex Pharmaceuticals’ Clinical Pipeline
In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.
Inside Vertex Pharmaceuticals’ Revenue Trend
In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.
What Analysts Recommend for Celgene in 2017
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.
How Incyte’s Valuation Has Changed since 1Q17 Results
Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue
Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.
Alexion Pharmaceuticals Projects Robust 2017 Revenue Performance
Alexion Pharmaceuticals (ALXN) expects to report revenue in the range of $3.4 billion–$3.5 billion in 2017.
Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17
To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.
Biogen Has Developed a Robust Access Strategy for Spinraza
In 1Q17, Biogen’s (BIIB) Spinraza earned revenues of $47.0 million, of which $46.0 million were from the US market.
Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17
Spinraza, Biogen’s (BIIB) SMA (spinal muscular atrophy) therapy, was approved by the FDA (U.S. Food and Drug Administration) on December 23, 2016.
Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?
In 2017, Regeneron expects its eye drug, Eylea, to witness single-digit revenue growth on a year-over-year basis. Eylea has continued to be the company’s major revenue driver in the year.
Failed Healthcare Bill Will Impact the Pharmaceutical Industry
Due to the failure of the new healthcare bill, major pharmaceutical companies witnessed a fall in their share prices from March 23, 2017, to March 27, 2017.
Ionis’s Subsidiary Akcea Therapeutics and Volanesorsen
Ionis Pharmaceuticals (IONS) formed Akcea Therapeutics, a wholly owned subsidiary, to develop and commercialize volanesorsen.
A Look at Ionis Pharmaceuticals’ Spinraza
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease.
Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.
How Do Analysts View Alnylam Pharmaceuticals in 2017?
Of the 15 analysts covering Alnylam Pharmaceuticals (ALNY) in February 2017, two rated the company as a “strong buy,” six rated it as a “buy,” and seven rated ALNY as a “hold.”
